European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, MyelomaApril 29, 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, NewsMarch 3, 2025
Register now to join the webinar ‘How do different countries make decisions on reimbursing new medicines?’Access, MPEMarch 6, 2025
Europe’s Beating Cancer Plan and its progress to date on rare cancersAccess, latest, NewsFebruary 28, 2025
The European Commission approves isatuximab + VRd combination therapy for newly diagnosed, transplant ineligible myeloma patientsAccess, Myeloma, NewsJanuary 24, 2025
Myeloma and AL amyloidosis ASH 2024 previewAccess, AL amyloidosis, CAR-T, MPE, MyelomaNovember 29, 2024
MPE encourages EMA to review its negative recommendation for ixazomibAccess, MPE, MyelomaAugust 16, 2016
EMA reconsiders and gives its positive opinion for the approval of ixazomibAccess, MyelomaSeptember 17, 2016
Delays in access to new cancer medicines and unjustifiable price rises for old ones disadvantage patients unnecessarilyAccessJanuary 28, 2017
Myeloma Patients Europe (MPE) relaunches Myeloma Access Atlas platformAccess, MPE, MyelomaOctober 19, 2021
